Johnson & Johnson begins marketing medications on TrumpRx website

Johnson & Johnson began marketing four medications on Trump administration's TrumpRx website, following a January agreement to lower costs in exchange for tariff exemption.

Objective Facts

Johnson & Johnson began officially marketing four of its medications on the Trump administration's TrumpRx website on Friday, April 25, 2026. The pharmaceutical company had announced in January that it entered a voluntary agreement with the Trump administration to lower costs for Americans by providing Medicaid access to affordable prescriptions and marketing its drugs on TrumpRx in exchange for exemption from the president's tariff agenda. One of the drugs offered on the White House's discounted pharmaceutical site is metformin, a popular prescription to treat Type 2 diabetes, along with metformin extended relief, Invokana (another diabetes medication), and Xarelto (a blood thinner). The addition of Johnson & Johnson pharmaceuticals to the TrumpRx site means the administration has more than doubled the number of drugs featured on the low-cost site since it first launched in February. However, the prescription drug prices on the site are only available to patients who are uninsured, or whose insurance doesn't cover it, and who must pay the full list price out of pocket.

Left-Leaning Perspective

Senate Democrats have aggressively criticized the TrumpRx initiative and J&J's participation. A report released by Sen. Bernie Sanders found that companies that signed drug pricing deals with Trump have raised the cost of hundreds of medications and launched new ones at an average price of $353,000 a year. Senate Finance Committee Ranking Member Ron Wyden released a report in April 2026 showing that these agreements are sweetheart deals for Big Pharma, and characterized Trump's efforts as "the greatest fraud when it comes to lower prescription drug prices." Wyden's report argues the agreements provide tax breaks, regulatory relief, and exemption from Trump's other attempts to lower drug prices. Left-leaning outlets have amplified concerns about the effectiveness and design of TrumpRx. Congressional Democrats on the Joint Economic Committee have warned that the website directs Americans to brand-name drugs rather than generics, meaning consumers frequently pay more than they should — in some cases, thousands of dollars annually. For example, a year's supply of the atrial fibrillation medication Tikosyn purchased at the TrumpRx discounted rate would cost about $4,000, whereas a generic version bought with a GoodRx coupon would cost just shy of $200 annually — a savings of roughly $3,800. Sen. Maggie Hassan accused the Trump administration of helping "Big Pharma line its pockets." Left-leaning coverage emphasizes that the discounts offered are minimal compared to available alternatives and that companies receiving tariff exemptions continue raising prices on many medications outside the TrumpRx platform. The focus is on what Democrats view as a transactional deal that benefits pharmaceutical companies more than patients.

Right-Leaning Perspective

Trump administration officials and Republican-aligned coverage have celebrated the J&J deal as evidence of successful private-sector negotiation. Johnson & Johnson CEO Joaquin Duato stated the agreement "shows that when the public and private sectors work together towards shared goals, we can deliver real results for patients and the US economy," and added he is "proud that Johnson & Johnson is answering President Trump's call to lower drug prices for everyday Americans while maintaining our role in improving and saving lives." The White House fact sheet notes that impending Section 232 tariffs have spurred approximately $400 billion in new investment commitments and highlights that despite being the world leader in R&D, the U.S. is heavily reliant on imports, threatening access to life-saving medications in a global supply chain disruption. Right-leaning analysis frames TrumpRx as a demonstration of Trump's dealmaking prowess and his ability to achieve cost reductions without congressional action. The White House stated: "President Trump recognizes that America must manufacture pharmaceutical products in order to be safe, secure, and healthy." Companies participating receive 3-year exemptions from any tariffs on imported pharmaceuticals that Trump may impose, with the president having repeatedly threatened such tariffs as leverage. Right-aligned coverage emphasizes manufacturing investments and the voluntary nature of the agreements, positioning them as business-friendly solutions that protect American security. Conservative outlets largely accept the administration's framing that TrumpRx represents genuine progress and highlight the substantial domestic manufacturing commitments J&J has made.

Deep Dive

Johnson & Johnson's April 25 launch on TrumpRx represents the latest major pharmaceutical company to join Trump's voluntary pricing agreement framework, which uses tariff threats as leverage to secure company participation. The core mechanism is straightforward: companies that sign Most-Favored-Nation (MFN) pricing agreements with HHS and meet domestic manufacturing commitments receive 3-year exemptions from 100% tariffs on patented pharmaceutical imports that Trump imposed in April 2026 under Section 232. As of April 23, 2026, the Administration has agreements with 17 companies: Pfizer, AstraZeneca, EMD Serono, Eli Lilly, Novo Nordisk, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, Sanofi, Johnson & Johnson, AbbVie, and Regeneron. What each perspective gets right: Democrats correctly identify that TrumpRx reaches only uninsured, cash-paying patients and that most Americans with insurance will see no immediate benefit. They are also correct that companies signing deals have continued raising prices on non-covered medications and launched new drugs at extremely high list prices—Johnson & Johnson's cancer drug Inlexzo launched at about $1 million, according to a Senate Democratic report. Republicans correctly point out that the deals do generate some discounts on specific medications and that the tariff threat has catalyzed announced manufacturing investments. What each side misses: Democrats understate the genuine Medicaid price reductions for covered drugs and the national security argument underlying tariff policy; Republicans downplay the limited reach of TrumpRx for the insured majority and the fact that tariff exemptions effectively reward non-compliance with price controls on medications outside the platform. The administration's claim that TrumpRx offers "the lowest prices in the developed world" contradicts its own data showing J&J drugs are still more expensive than in many foreign countries. What to watch: Congressional pressure for full disclosure of deal terms—the details of the agreements have so far not been made public, and Trump and Kennedy have urged Congress to codify the deals into law. A centerpiece of the agreements with Eli Lilly and Novo Nordisk fell apart earlier this week when Medicare delayed implementation of a program for insurers to cover the GLP-1 drugs. Additionally, whether Republicans in Congress, particularly those skeptical of most-favored-nation pricing on market grounds, will codify these ad hoc deals or allow them to expire as tariff exemptions sunset in 2029.

OBJ SPEAKING

Create StoryTimelinesVoter ToolsRegional AnalysisAll StoriesCommunity PicksUSWorldPoliticsBusinessHealthEntertainmentTechnologyAbout

Johnson & Johnson begins marketing medications on TrumpRx website

Johnson & Johnson began marketing four medications on Trump administration's TrumpRx website, following a January agreement to lower costs in exchange for tariff exemption.

Apr 24, 2026· Updated Apr 28, 2026
What's Going On

Johnson & Johnson began officially marketing four of its medications on the Trump administration's TrumpRx website on Friday, April 25, 2026. The pharmaceutical company had announced in January that it entered a voluntary agreement with the Trump administration to lower costs for Americans by providing Medicaid access to affordable prescriptions and marketing its drugs on TrumpRx in exchange for exemption from the president's tariff agenda. One of the drugs offered on the White House's discounted pharmaceutical site is metformin, a popular prescription to treat Type 2 diabetes, along with metformin extended relief, Invokana (another diabetes medication), and Xarelto (a blood thinner). The addition of Johnson & Johnson pharmaceuticals to the TrumpRx site means the administration has more than doubled the number of drugs featured on the low-cost site since it first launched in February. However, the prescription drug prices on the site are only available to patients who are uninsured, or whose insurance doesn't cover it, and who must pay the full list price out of pocket.

Left says: Senate Democrats, led by Ron Wyden, have called the Trump drug pricing deals "the greatest fraud when it comes to lower prescription drug prices," citing evidence that participating companies have raised prices on hundreds of medications while securing tariff exemptions and regulatory benefits.
Right says: Johnson & Johnson CEO Duato stated: "I'm proud that Johnson & Johnson is answering President Trump's call to lower drug prices for everyday Americans while maintaining our role in improving and saving lives and ensuring that the United States continues to lead the world in health care innovation."
✓ Common Ground
Several voices on the left and right acknowledge that high prescription drug prices represent a significant problem for American patients and that some form of policy intervention is needed, even if they disagree sharply on whether TrumpRx achieves this goal.
Both sides recognize the importance of domestic pharmaceutical manufacturing and supply chain resilience, though they differ on whether tariffs and direct industry deals are the right mechanisms to achieve it.
Republicans have historically opposed health policies that interfere with the free market; many spoke against giving Medicare authority to negotiate drug prices in Biden's 2022 reconciliation law. Some Republican lawmakers, including Speaker Mike Johnson, have expressed skepticism about most-favored-nation pricing, with Sen. Bill Cassidy raising concerns that the policy could dampen research and development. This suggests mild disagreement within the right itself about whether Trump's approach fully aligns with conservative market principles.
Both sides acknowledge that TrumpRx has limitations for the insured majority—most people have coverage through work, the individual insurance market or government programs like Medicaid and Medicare, which shield them from much of the cost.
Objective Deep Dive

Johnson & Johnson's April 25 launch on TrumpRx represents the latest major pharmaceutical company to join Trump's voluntary pricing agreement framework, which uses tariff threats as leverage to secure company participation. The core mechanism is straightforward: companies that sign Most-Favored-Nation (MFN) pricing agreements with HHS and meet domestic manufacturing commitments receive 3-year exemptions from 100% tariffs on patented pharmaceutical imports that Trump imposed in April 2026 under Section 232. As of April 23, 2026, the Administration has agreements with 17 companies: Pfizer, AstraZeneca, EMD Serono, Eli Lilly, Novo Nordisk, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, Sanofi, Johnson & Johnson, AbbVie, and Regeneron.

What each perspective gets right: Democrats correctly identify that TrumpRx reaches only uninsured, cash-paying patients and that most Americans with insurance will see no immediate benefit. They are also correct that companies signing deals have continued raising prices on non-covered medications and launched new drugs at extremely high list prices—Johnson & Johnson's cancer drug Inlexzo launched at about $1 million, according to a Senate Democratic report. Republicans correctly point out that the deals do generate some discounts on specific medications and that the tariff threat has catalyzed announced manufacturing investments. What each side misses: Democrats understate the genuine Medicaid price reductions for covered drugs and the national security argument underlying tariff policy; Republicans downplay the limited reach of TrumpRx for the insured majority and the fact that tariff exemptions effectively reward non-compliance with price controls on medications outside the platform. The administration's claim that TrumpRx offers "the lowest prices in the developed world" contradicts its own data showing J&J drugs are still more expensive than in many foreign countries.

What to watch: Congressional pressure for full disclosure of deal terms—the details of the agreements have so far not been made public, and Trump and Kennedy have urged Congress to codify the deals into law. A centerpiece of the agreements with Eli Lilly and Novo Nordisk fell apart earlier this week when Medicare delayed implementation of a program for insurers to cover the GLP-1 drugs. Additionally, whether Republicans in Congress, particularly those skeptical of most-favored-nation pricing on market grounds, will codify these ad hoc deals or allow them to expire as tariff exemptions sunset in 2029.

◈ Tone Comparison

Left-leaning coverage uses terms like "fraud," "sweetheart deals," and "price-gouging" to characterize the agreements, emphasizing deception and corporate benefit over patient welfare. Right-leaning and administration messaging uses triumphalist language like "the most impactful prescription price reset in the history of our country" and emphasizes dealmaking prowess, manufacturing jobs, and national security.